@article{24e37473c79748c18d6742c8876c04cf,
title = "Chronic lymphocytic leukaemia Australasian consensus practice statement",
abstract = "Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next-generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B-cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment-na{\"i}ve and relapsed/refractory disease, particularly for patients with high-risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS-CoV-2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.",
keywords = "CLL, consensus, diagnosis, management",
author = "Anderson, {Mary A.} and Rory Bennett and Xavier Badoux and Giles Best and Nicole Chia and Tara Cochrane and Gavin Cull and Kyle Crassini and Rosemary Harrup and Sharon Jackson and Bryone Kuss and Masa Lasica and Lew, {Thomas E.} and Paula Marlton and Stephen Opat and Emma Palfreyman and Polizzotto, {Mark N.} and Sumita Ratnasingam and Seymour, {John F.} and Asha Soosapilla and Dipti Talaulikar and Tam, {Constantine S.} and Robert Weinkove and Joel Wight and Mulligan, {Stephen P.}",
note = "Funding Information: A special thanks to learned colleagues who provided invaluable feedback on this consensus statement but could not be listed as authors, including Professor Andrew Roberts (Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia), Professor Andrew Grigg (Department Clinical Haematology, Austin Hospital, Heidelberg, Melbourne, Australia), Professor Judith Trotman (Haematology Department, University of Sydney, Concord, NSW, Australia), Associate Professor Eliza Hawkes (Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, Victoria, Australia), Professor Chan Cheah (Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia) and Dr Kah Lok Chan (Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia). This consensus statement has been endorsed by (i) the Scientific Advisory Committee of the Australian Leukaemia and Lymphoma Group, (ii) the Australian Lymphoma Alliance and (iii) the Haematology Society of Australia and New Zealand. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians. Funding Information: Conflict of Interest: Dr M. A. Anderson is an employee of the Walter and Eliza Hall Institute, which receives milestone payments in relation to venetoclax, in which she is entitled to a share. Dr M. A. Anderson receives honoraria from Abbvie, AstraZeneca, Janssen, Gilead, Novartis, Takeda, MSD and CSL. A/Prof T. Cochrane receives research funding from Beigene. Dr G. Cull has received disclosures for the last 24 months and research funding from Beigene, AstraZeneca and Glycomimetics. Dr R. Harrup serves on the AstraZeneca advisory board. Dr S. Jackson receives honoraria and advisory board participation for Abbvie. Dr P. Marlton: Advisory Board participation and/or speaker fees from Abbvie, Astellas, AstraZeneca, Beigene, Gilead, Janssen, Jazz, MSD, Novartis, Otsuka, Servier, Pfizer and Roche. Prof C. S. Tam receives honoraria from AbbVie, AstraZeneca, Janssen, Beigene and LOXO and research funding from AbbVie, Janssen and Beigene. Dr R. Weinkove receives speaker fees and advisory board participation for Abbvie and Janssen and speaker fees for Beigene. Dr J. Wight receives honoraria, travel funding and advisory boards from Abbvie, Janssen and MSD. Prof S. P. Mulligan receives honoraria or advisory board participation for Abbvie, AstraZeneca, Janssen and Beigene. Dr E. Palfreyman receives honoraria and advisory board participation from Abbvie and AstraZeneca. Dr T. E. Lew is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to venetoclax and is a recipient of a share in royalties. Prof J. F. Seymour: AbbVie; honoraria, membership on an entity's board of directors or advisory committees, research funding, speaker's bureau; Janssen; honoraria, membership on an entity's board of directors or advisory committee; TG Therapeutics; consultancy; F. Hoffman‐La Roche Ltd.; consultancy, honoraria, membership on an entity's board of directors or advisory committee, research funding, speaker's bureau; Celgene; consultancy, research funding, speaker's bureau; BMS; honoraria, membership on an entity's board of directors or advisory committee; Gilead; honoraria, membership on an entity's board of directors or advisory committee; Genor Biopharma; membership on an entity's board of directors or advisory committee. No conflicts of interest are declared for the remaining authors. Publisher Copyright: {\textcopyright} 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.",
year = "2023",
month = sep,
doi = "10.1111/imj.16207",
language = "English",
volume = "53",
pages = "1678--1691",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "John Wiley & Sons",
number = "9",
}